keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/28546850/knowledge-and-management-of-chronic-spontaneous-urticaria-in-latin-america-a-cross-sectional-study-in-ecuador
#1
A Cherrez, M Maurer, K Weller, J C Calderon, D Simancas-Racines, I Cherrez Ojeda
BACKGROUND: The current EAACI/GA(2)LEN/EDF/WAO guideline for urticaria provide specific recommendations for the diagnostic workup and treatment of patients with chronic spontaneous urticaria (CsU). This study explored if physicians in Ecuador know these recommendations and implement them in their actual clinical practice for CsU. METHODS: We investigated physicians who treat CsU patients in a cross-sectional study using a standardized questionnaire. Descriptive statistics were employed, adjusted logistic regression was performed to assess the link of guideline knowledge and use of therapy...
2017: World Allergy Organization Journal
https://www.readbyqxmd.com/read/28537934/alternative-treatments-for-chronic-spontaneous-urticaria-beyond-the-guideline-algorithm
#2
Gino A Vena, Marcus Maurer, Nicoletta Cassano, Torsten Zuberbier
PURPOSE OF REVIEW: The international EAACI/GALEN/EDF/WAO guideline suggests a stepwise approach for the therapeutic management of chronic spontaneous urticaria (CSU), outlined in an algorithm. The aim of this article is to summarize and review the evidence available on alternative treatment options for CSU outside of this algorithm. RECENT FINDINGS: Although CSU is a common disease, there are a limited number of high-quality studies, and only antihistamines and omalizumab are licensed for its treatment...
May 22, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28535776/the-role-of-anti-ige-omalizumab-xolair-in-the-management-of-severe-recalcitrant-paediatric-atopic-eczema-adapt-statistical-analysis-plan
#3
Tao Chen, Susan Chan, Gideon Lack, Suzie Cro, Victoria R Cornelius
BACKGROUND: The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and safety of omalizumab for children with severe atopic eczema. This article describes the detailed statistical analysis plan for the ADAPT as an update to the published protocol and is submitted prior to knowing all outcomes. METHOD AND DESIGN: The ADAPT is a randomised, double-blind, placebo-controlled trial with a primary objective to determine whether anti-IgE reduces eczema severity as assessed by the validated eczema score (objective SCORAD) after 24 weeks of treatment in children with severe eczema...
May 23, 2017: Trials
https://www.readbyqxmd.com/read/28532191/cost-effectiveness-of-omalizumab-add-on-to-standard-of-care-therapy-in-patients-with-uncontrolled-severe-allergic-asthma-in-a-brazilian-healthcare-setting
#4
Cibele Suzuki, Nilceia Lopes da Silva, Praveen Kumar, Purnima Pathak, Siew Hwa Ong
OBJECTIVE: Omalizumab add-on to standard-of-care therapy has proven to be efficacious in severe asthma patients for whom exacerbations cannot be controlled otherwise. Moreover, evidence from different healthcare settings suggests reduced healthcare resource utilization with omalizumab. Based on these findings, we aimed to assess the cost effectiveness of the addition of omalizumab to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting...
May 22, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28517027/lung-function-parameters-in-omalizumab-responder-patients-an-interesting-tool
#5
F Paganin, G Mangiapan, A Proust, A Prudhomme, J Attia, S Marchand-Adam, F Pellet, F Milhe, B Melloni, A Bernady, C Raspaud, C Nocent, P Berger, L Guilleminault
BACKGROUND: Omalizumab, an anti-IgE antibody, is used to treat patients with severe allergic asthma. The evolution of lung function parameters over time and the difference between omalizumab responder and non-responder patients remain inconclusive. The objective of this real-life study was to compare the changes in FEV1 of omalizumab responders and non-responders at 6 months. METHODS: A multicenter analysis was performed in 10 secondary and tertiary institutions...
May 18, 2017: Allergy
https://www.readbyqxmd.com/read/28513247/use-of-non-biologic-treatments-in-antihistamine-refractory-chronic-urticaria-a-review-of-published-evidence
#6
Jesper Grønlund Holm, Ilya Ivyanskiy, Simon Francis Thomsen
BACKGROUND: Knowledge of effectiveness and safety of the non-biologic, non-antihistamine treatments used for chronic urticaria is important as in some cases the principal guideline-recommended drug; omalizumab, has limited effect, side effects, or is too expensive or unavailable. Herein we systematically review the evidence for the use of the non-biologic treatments in antihistamine-refractory chronic urticaria. METHODS: We performed a systematic review of the literature using PubMed and Webofscience and identified studies that reported use of one or more of the non-biological, non-antihistamine treatment options for chronic urticaria...
May 17, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28501884/the-effect-of-systemic-treatments-on-periostin-expression-reflects-their-interference-with-the-eosinophilic-inflammation-in-chronic-rhinosinusitis-with-nasal-polyps
#7
E De Schryver, L Derycke, L Calus, G Holtappels, P W Hellings, T Van Zele, C Bachert, P Gevaert
BACKGROUND: Periostin is a recently discovered biomarker for eosinophilic inflammation. Chronic rhinosinusitis with nasal polyps is a T-helper 2-skewed chronic inflammatory airway disease. Medical treatments aim to relieve symptoms and maintain clinical control by interfering with the inflammatory cascade. The effect on nasal and serum periostin levels is however yet unknown. We aimed to evaluate the effect of omalizumab, mepolizumab, methylprednisolone and doxycycline on nasal and systemic periostin expression...
May 14, 2017: Rhinology
https://www.readbyqxmd.com/read/28500690/tnf-receptor-associated-periodic-syndrome-traps-mimicking-chronic-spontaneous-urticaria
#8
S Aurich, J C Simon, R Treudler
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare (about one per million) autosomal dominant autoinflammatory disease being typically characterized by recurrent fever episodes accompanied by variable gastrointestinal, musculoskeletal, neurological, lymphoid, urogenital and skin symptoms (table 1) [1-3]. We report on a 21 year old non atopic male with prediagnosed IgA deficiency, Marfan syndrome and hypothyroidism who first presented in our university allergy centre with three year history of antihistamine resistant, only slightly itching urticarial rash being accompanied by fatigue...
May 13, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28497924/real-life-efficacy-of-omalizumab-after-9-years-of-follow-up
#9
Francesco Menzella, Carla Galeone, Debora Formisano, Claudia Castagnetti, Patrizia Ruggiero, Anna Simonazzi, Luigi Zucchi
Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and long-acting β2-agonists in patients with suboptimal control of severe asthma. Patients with severe asthma will typically require chronic treatment, although due to the limited amount of data available there are still some concerns about the safety and efficacy of long-term therapy with omalizumab. Herein, in an extension of a previous 4-year study, we report disease-related outcomes of 8 patients with severe persistent allergic asthma who have been followed for a total of 9 years in a real-life setting...
July 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/28497679/disappearance-of-severe-oral-allergy-syndrome-following-omalizumab-treatment
#10
R Asero
The first case of disappearance of apple-induced oral allergy syndrome in a birch pollen-allergic patient following omalizumab treatment is reported. This observation in a case of type 2 food allergy suggests that omalizumab is potentially an effective preventive treatment for patients with severe, type 1 food allergies.
May 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28492605/severe-refractory-atopic-dermatitis-with-elevated-serum-ige-treated-with-omalizumab
#11
Stephen A Switlyk, Andrea L Taylor, Erich M Gaertner
No abstract text is available yet for this article.
April 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28474101/-chronic-urticaria-in-childhood-rational-diagnostics-and-treatment
#12
H Ott
Chronic urticaria (CU) is defined by episodes of urticaria with or without angioedema, which recur daily or nearly daily over more than 6 weeks. Sudden manifestations of CU with or without known causes are termed chronic spontaneous urticaria, which is differentiated from chronic inducible urticaria. The differential diagnoses of CU in childhood range from self-limiting dermatoses to severe systemic diseases. Further targeted steps are taken to detect potential trigger factors or underlying illnesses only if suspicion arises on anamnestic grounds and CU is best treated in accordance with international guidelines...
May 4, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28469716/allergic-bronchopulmonary-aspergillosis-in-patients-with-cystic-fibrosis
#13
REVIEW
Ibrahim Ahmed Janahi, Abdul Rehman, Amal Rashid Al-Naimi
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder that often occurs in patients with asthma or cystic fibrosis (CF) and is characterized by a hypersensitivity response to the allergens of the fungus Aspergillus fumigatus. In patients with CF, growth of A. fumigatus hyphae within the bronchial lumen triggers an immunoglobulin E (IgE)-mediated hypersensitivity response that results in airway inflammation, bronchospasm, and bronchiectasis. In most published studies, the prevalence of ABPA is about 8...
April 2017: Annals of Thoracic Medicine
https://www.readbyqxmd.com/read/28459601/omalizumab-versus-mepolizumab-as-add-on-therapy-in-asthma-patients-not-well-controlled-on-at-least-an-inhaled-corticosteroid-a-network-meta-analysis
#14
Zahi Nachef, Amita Krishnan, Terry Mashtare, Tingting Zhuang, M Jeffery Mador
OBJECTIVE: The purpose of this study is to examine the comparative efficacy of Omalizumab (OMA) and Mepolizumab (Mepo) in the treatment of severe asthma by performing a network meta-analysis. METHOD: Data Sources: A systematic review of the literature was performed through four databases from their inception to February 2016. STUDY SELECTIONS: Randomized control trials and cohort studies were considered if they addressed the individual efficacy of OMA and Mepo in the treatment of asthma that was not well controlled on inhaled corticosteroids (ICSs) with or without other agents...
May 1, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/28457893/improvement-in-the-quality-of-life-of-patients-with-chronic-spontaneous-urticaria-treated-with-omalizumab-in-real-life
#15
Itzíar Larrea-Baca, María Gurpegui-Resano
OBJECTIVE: Evaluation of the impact on the quality of life (QOL) relating to health in patients with chronic urticaria (CSU) treated with omalizumab. METHOD: Longitudinal descriptive observational study of quality of life based on18 patients with chronic urticaria ≥12 years treated with omalizumab. Changes in QOL examined at 1 month (T1), at 6 months (T6) and 12 months (T12), by: Visual Analogical Scale (UAS), specific urticaria QOL questionnaire (CU-Q2oL), general health questionnaire (SF-36) and activity of urticaria questionnaire (Score UAS7)...
April 27, 2017: Enfermería Clínica
https://www.readbyqxmd.com/read/28457471/response-to-omalizumab-in-solar-urticaria-report-of-3-cases
#16
P Rodríguez-Jiménez, P Chicharro, A Pérez-Plaza, D de Argila
We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H1 antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. The third experienced no improvement and developed a mild local reaction to the injected medication. We conclude that omalizumab may offer a potentially safe, useful alternative for patients with solar urticaria who do not respond to conventional therapy...
April 27, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28452145/how-to-manage-chronic-urticaria-beyond-guidelines-a-practical-algorithm
#17
Krzysztof Rutkowski, Clive E H Grattan
Chronic urticaria (CU) is a disease characterised by pruritic weals, angio-oedema or both occurring for at least 6 weeks. It encompasses spontaneous and inducible urticarias. The national and international guidelines outline the principles of treatment. Omalizumab, an anti-immunoglobulin E monoclonal antibody has transformed the management of many severe and treatment-refractory patients. However, current UK guidance on its use does not address the needs of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema without weals as a presentation of CU and omalizumab non-responders...
April 28, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28441991/in-vitro-impact-of-anti-immunoglobulin-e-monoclonal-antibodies-including-omalizumab-on-whole-blood-basophil-histamine-release-assessment-of-direct-induction-of-basophil-histamine-release-and-evaluation-of-modulation-of-allergen-induced-basophil-histamine-release
#18
Krzysztof Kowal, Pawel Bielecki, Ilona V DuBuske, Lawrence M DuBuske
AIM: The aim of this study was to evaluate the potential of anti-immunoglobulin E (IgE) and/or anti-IgE-IgE immune complexes to release histamine from peripheral blood basophils. In addition, a potential modulating effect of anti-IgE-IgE complexes on allergen-induced peripheral blood basophil histamine release was evaluated. METHODS: Whole blood basophil histamine release (WBB-HR) tests done by using glass-fiber-based microtiter plates were performed in 62 patients with allergic rhinitis and/or asthma sensitized to perennial allergens...
May 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/28438838/allosteric-mechanism-of-action-of-the-therapeutic-anti-ige-antibody-omalizumab
#19
Anna M Davies, Elizabeth G Allan, Anthony H Keeble, Jean Delgado, Benjamin P Cossins, Alkistis N Mitropoulou, Marie O Y Pang, Tom Ceska, Andrew J Beavil, Graham Craggs, Marta Westwood, Alistair J Henry, James M McDonnell, Brian J Sutton
Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically-approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells and antigen-presenting cells. We solved the crystal structure of the complex between an omalizumab-derived Fab and IgE-Fc, with one Fab bound to each Cϵ3 domain. Free IgE-Fc adopts an acutely bent structure, but in the complex it is only partially bent, with large-scale conformational changes in the Cϵ3 domains that inhibit the interaction with FcϵRI...
April 24, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28435464/clinical-efficacy-of-omalizumab-in-chronic-spontaneous-urticaria-is-associated-with-a-reduction-of-fc%C3%AE%C2%B5ri-positive-cells-in-the-skin
#20
Martin Metz, Petra Staubach, Andrea Bauer, Randolf Brehler, Janine Gericke, Michael Kangas, Joanna Ashton-Chess, Philip Jarvis, Panayiotis Georgiou, Janice Canvin, Rainer Hillenbrand, Veit J Erpenbeck, Marcus Maurer
Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omalizumab on levels of high affinity IgE receptor-positive (FcεRI(+)) and IgE-positive (IgE(+)) dermal cells and blood basophils. Treatment efficacy and safety were also assessed. Study design. In a double-blind study, CSU patients aged 18‑75 years were randomized to receive 300 mg omalizumab (n=20) or placebo (n=10) subcutaneously every 4 weeks for 12 weeks...
2017: Theranostics
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"